Screener / SEC EDGAR /CIK 0000818479 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Dental Equipment & Supplies

DENTSPLY SIRONA Inc. XRAY

Compare with peers Embed

XRAY among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
-3.0%145th of 155 · median +10.5%
Net margin
-4.1%15.3%
-3.4%115th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-8.9%112th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
2.9%106th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.6292nd of 108 · median 0.69

XRAY and 9 peers, year by year

The 9 Health care companies closest to XRAY in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
XRAY DENTSPLY SIRONA Inc. FY2025 $3.7B−3.0%50.0%−11.5%−16.2%2.8%−44.7%1.76
BMRN Biomarin Pharmaceutical Inc FY2025 $3.2B+12.9%-12.7%10.8%22.5%5.7%0.10
VEEV Veeva Systems FY2026 $3.2B+16.3%75.5%28.7%28.4%-12.6%-
NBIX Neurocrine Biosciences Inc FY2025 $2.9B+21.4%-21.6%16.7%26.2%14.7%-
ACHC Acadia Healthcare Company, Inc. FY2025 $3.3B+5.0%--−33.3%−13.3%−56.6%1.28
WST West Pharmaceutical Services FY2025 $3.1B+6.3%35.9%19.0%16.1%15.3%15.5%0.06
SGRY Surgery Partners, Inc. FY2025 $3.3B+6.2%-11.8%−2.4%5.9%−4.5%2.18
AMRX Amneal Pharmaceuticals, Inc. FY2025 $3.0B+8.0%36.9%13.1%2.4%8.9%n/mn/m
PODD Insulet Corporation FY2025 $2.7B+30.7%71.6%17.5%9.1%13.9%16.3%0.63
UTHR UNITED THERAPEUTICS Corp FY2025 $3.2B+10.6%87.9%46.9%41.9%32.7%18.8%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2016 to FY2025 · 10-K XBRL

XRAYDENTSPLY SIRONA Inc.
FY2016 revenue $3.7BFY2017 revenue $4.0BFY2018 revenue $4.0BFY2019 revenue $4.0BFY2020 revenue $3.3BFY2021 revenue $4.2BFY2022 revenue $3.9BFY2023 revenue $4.0BFY2024 revenue $3.8BFY2025 revenue $3.7B FY2016 net margin 11.5%FY2017 net margin −38.8%FY2018 net margin −25.4%FY2019 net margin 6.4%FY2020 net margin −2.2%FY2021 net margin 9.7%FY2022 net margin −24.2%FY2023 net margin −3.3%FY2024 net margin −24.0%FY2025 net margin −16.2% FY2016FY2025
Revenue$3.7B Growth−3.0% Net margin−16.2%
BMRNBiomarin Pharmaceutical Inc
FY2016 revenue $1.1BFY2017 revenue $1.3BFY2018 revenue $1.5BFY2019 revenue $1.7BFY2020 revenue $1.9BFY2021 revenue $1.8BFY2022 revenue $2.1BFY2023 revenue $2.4BFY2024 revenue $2.9BFY2025 revenue $3.2B FY2016 net margin −56.4%FY2017 net margin −8.9%FY2018 net margin −5.2%FY2019 net margin −1.4%FY2020 net margin 45.9%FY2021 net margin −3.5%FY2022 net margin 6.8%FY2023 net margin 6.9%FY2024 net margin 15.0%FY2025 net margin 10.8% FY2016FY2025
Revenue$3.2B Growth+12.9% Net margin10.8%
VEEVVeeva Systems
FY2016 revenue $409.2MFY2017 revenue $550.5MFY2018 revenue $690.6MFY2019 revenue $862.2MFY2020 revenue $1.1BFY2021 revenue $1.5BFY2022 revenue $1.9BFY2023 revenue $2.2BFY2024 revenue $2.4BFY2025 revenue $2.7B FY2016 net margin 13.3%FY2017 net margin 14.1%FY2018 net margin 21.9%FY2019 net margin 26.7%FY2020 net margin 27.3%FY2021 net margin 25.9%FY2022 net margin 23.1%FY2023 net margin 22.6%FY2024 net margin 22.2%FY2025 net margin 26.0% FY2016FY2025
Revenue$2.7B Growth+16.2% Net margin26.0%
NBIXNeurocrine Biosciences Inc
FY2016 revenue $15.0MFY2017 revenue $161.6MFY2018 revenue $451.2MFY2019 revenue $788.1MFY2020 revenue $1.0BFY2021 revenue $1.1BFY2022 revenue $1.5BFY2023 revenue $1.9BFY2024 revenue $2.4BFY2025 revenue $2.9B FY2016 net margin −940.6%FY2017 net margin −88.2%FY2018 net margin 4.7%FY2019 net margin 4.7%FY2020 net margin 38.9%FY2021 net margin 7.9%FY2022 net margin 10.4%FY2023 net margin 13.2%FY2024 net margin 14.5%FY2025 net margin 16.7% FY2016FY2025
Revenue$2.9B Growth+21.4% Net margin16.7%
ACHCAcadia Healthcare Company, Inc.
FY2016 revenue $2.8BFY2017 revenue $2.8BFY2018 revenue $1.9BFY2019 revenue $2.0BFY2020 revenue $2.1BFY2021 revenue $2.3BFY2022 revenue $2.6BFY2023 revenue $2.9BFY2024 revenue $3.2BFY2025 revenue $3.3B FY2016 net margin 0.2%FY2017 net margin 7.0%FY2018 net margin −9.2%FY2019 net margin 5.4%FY2020 net margin −32.2%FY2021 net margin 8.2%FY2022 net margin 10.5%FY2023 net margin −0.7%FY2024 net margin 8.1%FY2025 net margin −33.3% FY2016FY2025
Revenue$3.3B Growth+5.0% Net margin−33.3%
WSTWest Pharmaceutical Services
FY2016 revenue $1.5BFY2017 revenue $1.6BFY2018 revenue $1.7BFY2019 revenue $1.8BFY2020 revenue $2.1BFY2021 revenue $2.8BFY2022 revenue $2.9BFY2023 revenue $2.9BFY2024 revenue $2.9BFY2025 revenue $3.1B FY2016 net margin 9.5%FY2017 net margin 9.4%FY2018 net margin 12.0%FY2019 net margin 13.1%FY2020 net margin 16.1%FY2021 net margin 23.4%FY2022 net margin 20.3%FY2023 net margin 20.1%FY2024 net margin 17.0%FY2025 net margin 16.1% FY2016FY2025
Revenue$3.1B Growth+6.3% Net margin16.1%
SGRYSurgery Partners, Inc.
FY2016 revenue $1.1BFY2018 revenue $1.8BFY2019 revenue $1.8BFY2020 revenue $1.9BFY2021 revenue $2.2BFY2022 revenue $2.5BFY2023 revenue $2.7BFY2024 revenue $3.1BFY2025 revenue $3.3B FY2016 net margin 0.8%FY2018 net margin −11.6%FY2019 net margin −4.1%FY2020 net margin −6.2%FY2021 net margin −3.2%FY2022 net margin −2.2%FY2023 net margin −0.4%FY2024 net margin −5.4%FY2025 net margin −2.4% FY2016FY2025
Revenue$3.3B Growth+6.2% Net margin−2.4%
AMRXAmneal Pharmaceuticals, Inc.
FY2016 revenue $1.0BFY2017 revenue $1.0BFY2018 revenue $1.7BFY2019 revenue $1.6BFY2020 revenue $2.0BFY2021 revenue $2.1BFY2022 revenue $2.2BFY2023 revenue $2.4BFY2024 revenue $2.8BFY2025 revenue $3.0B FY2016 net margin 0.0%FY2017 net margin 0.0%FY2018 net margin −1.2%FY2019 net margin −37.1%FY2020 net margin 3.4%FY2021 net margin 0.6%FY2022 net margin −12.2%FY2023 net margin −3.5%FY2024 net margin −4.2%FY2025 net margin 2.4% FY2016FY2025
Revenue$3.0B Growth+8.0% Net margin2.4%
PODDInsulet Corporation
FY2016 revenue $367.0MFY2017 revenue $463.8MFY2018 revenue $563.8MFY2019 revenue $738.2MFY2020 revenue $904.4MFY2021 revenue $1.1BFY2022 revenue $1.3BFY2023 revenue $1.7BFY2024 revenue $2.1BFY2025 revenue $2.7B FY2016 net margin −7.9%FY2017 net margin −5.8%FY2018 net margin 0.6%FY2019 net margin 1.6%FY2020 net margin 0.8%FY2021 net margin 1.5%FY2022 net margin 0.4%FY2023 net margin 12.2%FY2024 net margin 20.2%FY2025 net margin 9.1% FY2016FY2025
Revenue$2.7B Growth+30.7% Net margin9.1%
UTHRUNITED THERAPEUTICS Corp
FY2016 revenue $1.6BFY2017 revenue $1.7BFY2018 revenue $1.6BFY2019 revenue $1.4BFY2020 revenue $1.5BFY2021 revenue $1.7BFY2022 revenue $1.9BFY2023 revenue $2.3BFY2024 revenue $2.9BFY2025 revenue $3.2B FY2016 net margin 44.6%FY2017 net margin 24.2%FY2018 net margin 36.2%FY2019 net margin −7.2%FY2020 net margin 34.7%FY2021 net margin 28.2%FY2022 net margin 37.6%FY2023 net margin 42.3%FY2024 net margin 41.5%FY2025 net margin 41.9% FY2016FY2025
Revenue$3.2B Growth+10.6% Net margin41.9%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2016 to FY2025

Revenue as reported in the 10-K.

100 500 2000 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: $1.1B, $1.3B, $1.5B, $1.7B, $1.9B, $1.8B, $2.1B, $2.4B, $2.9B, $3.2B BMRN VEEV: $409.2M, $550.5M, $690.6M, $862.2M, $1.1B, $1.5B, $1.9B, $2.2B, $2.4B, $2.7B VEEV NBIX: $15.0M, $161.6M, $451.2M, $788.1M, $1.0B, $1.1B, $1.5B, $1.9B, $2.4B, $2.9B NBIX ACHC: $2.8B, $2.8B, $1.9B, $2.0B, $2.1B, $2.3B, $2.6B, $2.9B, $3.2B, $3.3B ACHC WST: $1.5B, $1.6B, $1.7B, $1.8B, $2.1B, $2.8B, $2.9B, $2.9B, $2.9B, $3.1B WST SGRY: $1.1B, -, $1.8B, $1.8B, $1.9B, $2.2B, $2.5B, $2.7B, $3.1B, $3.3B SGRY AMRX: $1.0B, $1.0B, $1.7B, $1.6B, $2.0B, $2.1B, $2.2B, $2.4B, $2.8B, $3.0B AMRX PODD: $367.0M, $463.8M, $563.8M, $738.2M, $904.4M, $1.1B, $1.3B, $1.7B, $2.1B, $2.7B PODD UTHR: $1.6B, $1.7B, $1.6B, $1.4B, $1.5B, $1.7B, $1.9B, $2.3B, $2.9B, $3.2B UTHR XRAY: $3.7B, $4.0B, $4.0B, $4.0B, $3.3B, $4.2B, $3.9B, $4.0B, $3.8B, $3.7B XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. Each company's first year in the window is 100, on a log scale: a line twice as high has doubled. A gap is a year with no number. ACHC: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2016 to FY2025

Revenue against the fiscal year before.

−24.1% +978% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: +25.5%, +17.6%, +13.5%, +14.3%, +9.2%, −0.8%, +13.5%, +15.4%, +18.0%, +12.9% BMRN VEEV: -, +32.9%, +25.4%, +24.9%, +28.1%, +32.7%, +26.3%, +16.4%, +9.7%, +16.2% VEEV NBIX: −24.1%, +978%, +179%, +74.7%, +32.7%, +8.4%, +31.3%, +26.8%, +24.8%, +21.4% NBIX ACHC: -, +0.9%, +6.2%, +5.4%, +4.1%, +10.7%, +12.8%, +12.2%, +7.7%, +5.0% ACHC WST: +7.8%, +6.0%, +7.4%, +7.1%, +16.7%, +31.9%, +2.0%, +2.2%, −1.9%, +6.3% WST SGRY: +19.3%, -, -, +3.4%, +1.6%, +19.6%, +14.1%, +8.0%, +13.5%, +6.2% SGRY AMRX: -, +1.5%, +60.9%, −2.2%, +22.5%, +5.1%, +5.7%, +8.2%, +16.7%, +8.0% AMRX PODD: +39.1%, +26.4%, +21.6%, +30.9%, +22.5%, +15.1%, +18.8%, +30.0%, +22.1%, +30.7% PODD UTHR: +9.1%, +7.9%, −5.7%, −11.0%, +2.4%, +13.6%, +14.9%, +20.2%, +23.6%, +10.6% UTHR XRAY: +40.0%, +6.6%, −0.2%, +1.1%, −17.0%, +26.7%, −7.3%, +1.1%, −4.3%, −3.0% XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −24.1% to +978%. A gap is a year with no number. A ring marks where a line starts: VEEV, ACHC, AMRX have no earlier 10-K here.

Gross margin, FY2016 to FY2025

Gross profit / revenue.

21.7% 92.7% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 VEEV: 65.2%, 68.5%, 69.4%, 71.6%, 72.5%, 72.1%, 72.8%, 71.7%, 71.3%, 74.5% VEEV WST: 33.2%, 32.1%, 31.8%, 32.9%, 35.8%, 41.5%, 39.4%, 38.3%, 34.5%, 35.9% WST AMRX: 58.7%, 50.9%, 43.1%, 21.7%, 31.5%, 36.7%, 35.5%, 34.3%, 36.5%, 36.9% AMRX PODD: 57.5%, 59.8%, 65.7%, 65.1%, 64.4%, 68.4%, 61.7%, 68.3%, 69.8%, 71.6% PODD UTHR: -, -, -, 91.9%, 92.7%, 92.7%, 92.2%, 88.9%, 89.2%, 87.9% UTHR XRAY: 53.4%, 54.8%, 51.9%, 53.8%, 49.6%, 55.5%, 54.2%, 52.6%, 51.6%, 50.0% XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 21.7% to 92.7%. A gap is a year with no number. A ring marks where a line starts: UTHR has no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
XRAY Dec 53.4%54.8%51.9%53.8%49.6%55.5%54.2%52.6%51.6%50.0%
BMRN Dec ----------
VEEV Jan 65.2%68.5%69.4%71.6%72.5%72.1%72.8%71.7%71.3%74.5%
NBIX Dec ----------
ACHC Dec ----------
WST Dec 33.2%32.1%31.8%32.9%35.8%41.5%39.4%38.3%34.5%35.9%
SGRY Dec ----------
AMRX Dec 58.7%50.9%43.1%21.7%31.5%36.7%35.5%34.3%36.5%36.9%
PODD Dec 57.5%59.8%65.7%65.1%64.4%68.4%61.7%68.3%69.8%71.6%
UTHR Dec ---91.9%92.7%92.7%92.2%88.9%89.2%87.9%
Peer median58.1%55.3%54.4%65.1%64.4%68.4%61.7%68.3%69.8%71.6%

Operating margin, FY2016 to FY2025

Operating income / revenue.

−982.5% 66.4% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: −71.9%, −1.1%, −8.3%, −5.9%, −2.3%, −4.5%, 7.7%, 7.7%, 17.0%, 12.7% BMRN VEEV: 19.2%, 21.9%, 22.9%, 25.8%, 25.9%, 25.8%, 27.3%, 21.3%, 18.2%, 25.2% VEEV NBIX: −982.5%, −81.3%, 8.2%, 9.2%, 15.6%, 9.0%, 16.7%, 13.3%, 24.2%, 21.6% NBIX ACHC: 21.7%, 21.3%, 31.2%, 29.2%, -, -, -, -, -, - ACHC WST: 12.9%, 14.1%, 14.0%, 16.1%, 19.0%, 26.6%, 25.4%, 22.9%, 19.7%, 19.0% WST SGRY: 17.2%, -, 4.4%, 12.9%, 9.8%, 13.6%, 13.6%, 12.0%, 11.2%, 11.8% SGRY AMRX: 28.0%, 23.7%, −1.2%, −15.3%, 4.6%, 7.3%, −4.3%, 8.5%, 8.9%, 13.1% AMRX PODD: −2.9%, −1.6%, 4.9%, 6.8%, 5.7%, 11.5%, 2.9%, 13.0%, 14.9%, 17.5% PODD UTHR: 66.4%, 47.2%, 49.5%, −12.9%, 40.0%, 33.0%, 50.6%, 50.9%, 47.9%, 46.9% UTHR XRAY: 12.1%, −39.1%, −24.0%, 8.8%, −0.1%, 14.4%, −23.9%, −2.1%, −23.2%, −11.5% XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −982.5% to 66.4%. A gap is a year with no number.

Net margin, FY2016 to FY2025

Net income / revenue.

−940.6% 45.9% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: −56.4%, −8.9%, −5.2%, −1.4%, 45.9%, −3.5%, 6.8%, 6.9%, 15.0%, 10.8% BMRN VEEV: 13.3%, 14.1%, 21.9%, 26.7%, 27.3%, 25.9%, 23.1%, 22.6%, 22.2%, 26.0% VEEV NBIX: −940.6%, −88.2%, 4.7%, 4.7%, 38.9%, 7.9%, 10.4%, 13.2%, 14.5%, 16.7% NBIX ACHC: 0.2%, 7.0%, −9.2%, 5.4%, −32.2%, 8.2%, 10.5%, −0.7%, 8.1%, −33.3% ACHC WST: 9.5%, 9.4%, 12.0%, 13.1%, 16.1%, 23.4%, 20.3%, 20.1%, 17.0%, 16.1% WST SGRY: 0.8%, -, −11.6%, −4.1%, −6.2%, −3.2%, −2.2%, −0.4%, −5.4%, −2.4% SGRY AMRX: 0.0%, 0.0%, −1.2%, −37.1%, 3.4%, 0.6%, −12.2%, −3.5%, −4.2%, 2.4% AMRX PODD: −7.9%, −5.8%, 0.6%, 1.6%, 0.8%, 1.5%, 0.4%, 12.2%, 20.2%, 9.1% PODD UTHR: 44.6%, 24.2%, 36.2%, −7.2%, 34.7%, 28.2%, 37.6%, 42.3%, 41.5%, 41.9% UTHR XRAY: 11.5%, −38.8%, −25.4%, 6.4%, −2.2%, 9.7%, −24.2%, −3.3%, −24.0%, −16.2% XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −940.6% to 45.9%. A gap is a year with no number.

Free cash flow, FY2016 to FY2025

Cash from operations minus capital spending.

−$560.7M $1.1B FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: −$376.2M, −$208.0M, −$124.4M, −$96.8M, −$28.9M, $209.0M, $54.9M, $62.6M, $487.4M, $725.0M BMRN VEEV: $59.0M, $137.1M, $223.8M, $302.4M, $434.3M, -, -, -, -, - VEEV NBIX: −$110.3M, −$101.3M, $76.6M, $132.3M, $217.6M, $233.1M, $322.9M, $361.6M, $557.2M, $748.7M NBIX ACHC: $54.0M, $125.4M, $160.9M, $100.2M, $433.8M, $129.7M, $84.4M, $38.2M, −$560.7M, −$439.9M ACHC WST: $49.2M, $132.5M, $183.9M, $240.8M, $298.1M, $330.6M, $439.4M, $414.5M, $276.4M, $468.9M WST SGRY: $86.1M, -, $104.8M, $55.9M, $204.0M, $29.5M, $78.2M, $205.0M, $209.7M, $195.6M SGRY AMRX: −$7.7M, $139.4M, $167.1M, −$45.5M, $322.6M, $194.1M, $18.7M, $302.4M, $243.2M, $269.9M AMRX PODD: −$6.2M, −$32.5M, −$121.5M, −$65.3M, −$45.0M, −$180.0M, −$3.9M, $70.1M, $305.3M, $377.7M PODD UTHR: $605.6M, $387.9M, $594.0M, −$290.3M, $696.4M, $477.4M, $663.7M, $747.6M, $1.1B, $1.0B UTHR XRAY: $438.4M, $457.6M, $317.0M, $516.0M, $562.0M, $515.0M, $368.0M, $228.0M, $281.0M, $104.0M XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$560.7M to $1.1B. A gap is a year with no number.

FCF margin, FY2016 to FY2025

Free cash flow / revenue.

−735.3% 46.9% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: −33.7%, −15.8%, −8.3%, −5.7%, −1.6%, 11.3%, 2.6%, 2.6%, 17.1%, 22.5% BMRN VEEV: 14.4%, 24.9%, 32.4%, 35.1%, 39.3%, -, -, -, -, - VEEV NBIX: −735.3%, −62.7%, 17.0%, 16.8%, 20.8%, 20.6%, 21.7%, 19.2%, 23.7%, 26.2% NBIX ACHC: 1.9%, 4.4%, 8.4%, 5.0%, 20.8%, 5.6%, 3.2%, 1.3%, −17.8%, −13.3% ACHC WST: 3.3%, 8.3%, 10.7%, 13.1%, 13.9%, 11.7%, 15.2%, 14.1%, 9.6%, 15.3% WST SGRY: 7.5%, -, 5.9%, 3.1%, 11.0%, 1.3%, 3.1%, 7.5%, 6.7%, 5.9% SGRY AMRX: −0.8%, 13.5%, 10.1%, −2.8%, 16.2%, 9.3%, 0.8%, 12.6%, 8.7%, 8.9% AMRX PODD: −1.7%, −7.0%, −21.6%, −8.8%, −5.0%, −16.4%, −0.3%, 4.1%, 14.7%, 13.9% PODD UTHR: 37.9%, 22.5%, 36.5%, −20.0%, 46.9%, 28.3%, 34.3%, 32.1%, 37.6%, 32.7% UTHR XRAY: 11.7%, 11.5%, 8.0%, 12.8%, 16.8%, 12.2%, 9.4%, 5.8%, 7.4%, 2.8% XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −735.3% to 46.9%. A gap is a year with no number.

Return on equity, FY2016 to FY2025

Net income / shareholders' equity at the year end.

−100.4% 97.7% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: −22.8%, −4.2%, −2.6%, −0.8%, 20.8%, −1.5%, 3.1%, 3.4%, 7.5%, 5.7% BMRN VEEV: 10.4%, 11.4%, 16.7%, 18.6%, 18.1%, 16.8%, 14.7%, 13.1%, 11.3%, 12.2% VEEV NBIX: −44.8%, −38.3%, 4.4%, 5.8%, 36.2%, 6.5%, 9.0%, 11.2%, 13.2%, 14.7% NBIX ACHC: 0.3%, 7.8%, −7.5%, 4.3%, −35.4%, 7.6%, 9.7%, −0.8%, 8.3%, −56.6% ACHC WST: 12.9%, 11.8%, 14.8%, 15.4%, 18.7%, 28.3%, 21.8%, 20.6%, 18.4%, 15.5% WST SGRY: 97.7%, -, −50.8%, −25.2%, −100.4%, −6.5%, −2.7%, −0.6%, −9.4%, −4.5% SGRY AMRX: -, n/m, −3.9%, n/m, 22.4%, 3.7%, −90.7%, n/m, n/m, n/m AMRX PODD: −45.8%, −16.9%, 1.6%, 15.3%, 1.1%, 3.0%, 1.0%, 28.2%, 34.5%, 16.3% PODD UTHR: 38.6%, 19.9%, 21.1%, −3.8%, 15.2%, 12.0%, 15.2%, 16.5%, 18.5%, 18.8% UTHR XRAY: 5.3%, −23.4%, −19.7%, 5.0%, −1.5%, 8.2%, −24.9%, −4.0%, −46.9%, −44.7% XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −100.4% to 97.7%. A gap is a year with no number. A ring marks where a line starts: AMRX has no earlier 10-K here.

Debt / equity, FY2016 to FY2025

Total debt / shareholders' equity at the year end.

0.06 11.70 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: -, -, -, -, -, -, -, -, -, 0.10 BMRN ACHC: 1.52, 1.26, 1.37, 1.26, 1.64, 0.59, 0.49, 0.49, 0.64, 1.28 ACHC WST: 0.21, 0.15, 0.14, 0.16, 0.14, 0.11, 0.08, 0.07, 0.08, 0.06 WST SGRY: n/m, -, 5.75, 8.75, n/m, 2.72, 1.32, 1.41, 1.90, 2.18 SGRY AMRX: -, n/m, 5.25, 11.34, 9.17, 7.52, 8.79, n/m, n/m, n/m AMRX PODD: 5.27, 3.57, 2.79, 11.70, 1.75, 2.29, 2.94, 1.93, 1.14, 0.63 PODD XRAY: 0.19, 0.25, 0.32, 0.28, 0.46, 0.42, 0.52, 0.65, 1.12, 1.76 XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.06 to 11.70. A gap is a year with no number. A ring marks where a line starts: BMRN, SGRY, AMRX have no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
XRAY Dec 0.190.250.320.280.460.420.520.651.121.76
BMRN Dec ---------0.10
VEEV Jan ----------
NBIX Dec ----------
ACHC Dec 1.521.261.371.261.640.590.490.490.641.28
WST Dec 0.210.150.140.160.140.110.080.070.080.06
SGRY Dec n/m-5.758.75n/m2.721.321.411.902.18
AMRX Dec -n/m5.2511.349.177.528.79n/mn/mn/m
PODD Dec 5.273.572.7911.701.752.292.941.931.140.63
UTHR Dec ----------
Peer median1.521.262.798.751.702.291.320.950.890.63

EPS (diluted), FY2016 to FY2025

Diluted earnings per share, on today's share count after splits.

−$12.16 $27.86 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BMRN: −$3.81, −$0.67, −$0.44, −$0.13, $4.50, −$0.35, $0.75, $0.87, $2.21, $1.80 BMRN VEEV: $0.38, $0.53, $0.98, $1.47, $1.90, $2.36, $2.63, $3.00, $3.22, $4.32 VEEV NBIX: −$1.63, −$1.62, $0.22, $0.39, $4.16, $0.92, $1.56, $2.47, $3.29, $4.67 NBIX ACHC: $0.07, $2.30, −$2.01, $1.24, −$7.59, $2.10, $2.98, −$0.24, $2.78, −$12.16 ACHC WST: $1.91, $1.99, $2.74, $3.21, $4.57, $8.67, $7.73, $7.88, $6.69, $6.79 WST SGRY: $0.20, -, −$4.96, −$2.29, −$3.19, −$1.12, −$0.59, −$0.09, −$1.33, −$0.61 SGRY AMRX: -, -, −$0.16, −$2.74, $0.61, $0.07, −$0.86, −$0.48, −$0.38, $0.22 AMRX PODD: −$0.48, −$0.46, $0.05, $0.19, $0.10, $0.24, $0.07, $2.94, $5.78, $3.48 PODD UTHR: $15.25, $9.31, $13.39, −$2.39, $11.54, $10.06, $15.00, $19.81, $24.64, $27.86 UTHR XRAY: $1.94, −$6.76, −$4.51, $1.14, −$0.33, $1.87, −$4.41, −$0.62, −$4.48, −$3.00 XRAY
XRAY is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$12.16 to $27.86. A gap is a year with no number. A ring marks where a line starts: AMRX has no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out XRAY and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: XRAY's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XRAY/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.